Focuses on developing therapies for pain management and central nervous system disorders.
Eliem Therapeutics, Inc. is a forward-thinking clinical-stage biotechnology company specializing in the development of therapies targeting neuronal excitability disorders. These efforts are aimed at addressing significant gaps in treatment across chronic pain, neuropsychiatry, epilepsy, and other conditions affecting the central and peripheral nervous systems.
At the forefront of its innovation are two promising drug candidates. ETX-810, currently in Phase IIa clinical trials, focuses on chronic pain management. Meanwhile, ETX-155, undergoing Phase I trials, targets major depressive disorder, perimenopausal depression, and focal onset seizures. Additionally, Eliem Therapeutics is advancing preclinical pipeline programs including the Kv7 Program, which holds potential applications in pain management, epilepsy, and depression, as well as an Anxiolytic program aimed at treating generalized anxiety disorder.
Since its inception in 2018 and headquartered in Redmond, Washington, Eliem Therapeutics has rapidly emerged as a leader in therapeutic innovation for neurological and psychiatric conditions. By leveraging cutting-edge research and strategic development initiatives, the company is dedicated to improving patient outcomes and advancing the frontier of neuroscience-based treatments.